Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Sabra Health Care REIT Sees FY24 Normalized AFFO $1.39-$1.43

Author: Benzinga Newsdesk | May 08, 2024 04:33pm

2024 GUIDANCE

Sabra is reiterating 2024 earnings guidance ranges as follows (attributable to common stockholders, per diluted common share):

  • Net Income: $0.53 - $0.57
  • FFO: $1.33 - $1.37
  • Normalized FFO: $1.34 - $1.38
  • AFFO: $1.38 - $1.42
  • Normalized AFFO: $1.39 - $1.43

Earnings guidance above assumes no 2024 acquisition or disposition activity.

Commenting on the first quarter's results, Rick Matros, CEO and Chair, said, "As has been evident for several quarters, Sabra's portfolio continues to grow stronger, whether looking at coverage, occupancy, or NOI. Trailing-twelve-month SNF coverage saw a healthy 0.06x increase sequentially, to 1.79x, when excluding the impact of Provider Relief Funds. Our SHOP portfolio continues to improve, and this quarter's results - which faced a challenging year-over-year comp - are in line with our expectations embedded in guidance. Our balance sheet remains strong and is poised to support future growth.

Although we have no new investments to discuss this quarter, the pipeline has improved and with what we are working on, we expect to announce new investments on our second quarter call."

Posted In: SBRA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist